Simurosertib is under clinical development by Zai Lab and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Simurosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Simurosertib (ZL-2309) is under development for the treatment of multiple tumor types including solid tumor, esophageal squamous cell carcinoma and cervical cancer. The drug candidate is administered orally. It targets cell division cycle 7 (CDC7) protein kinase.
Zai Lab overview
Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies which address medical conditions with unmet needs in oncology. The company offering products pipeline includes Zejula Niraparib is a once-daily small molecule poly (ADP-ribose) polymerase 1/2inhibitor, Optune Tumor Treating Fields for cancer treatment, Qinlock Ripretinib and NUZYRA Omadacycline, a novel tetracycline-class antibacterial. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.
For a complete picture of Simurosertib’s drug-specific PTSR and LoA scores, buy the report here.